Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

I-tech: Proposed non-renewal of Selektope in the EU - ABG

I-tech

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* European Commission drafts proposal for non-renewal of Selektope* Limited impact on near-term estimates, EU ~2% of total sales* Voting expected to occur some time in H1'26, final decision in mid-26European Commission drafts proposal for non-renewal of SelektopeThis morning, I-Tech issued a press release stating that the European Commission has drafted a proposal for the non-renewal of Medetomidine (Selektope). The draft implementation act, which is yet to be published, will be discussed at the Standing Committee on Biocidal Products (SCBP) meeting taking place at 10 December. Several steps need to be completed before the final decision is made, and I-Tech expects voting on the implementation act to occur some time in H1'26. We expect a final decision in mid-26.Limited impact to near-term estimatesIn the event of an EU ban, the direct effects on I-Tech would be relatively minor, given that the EU currently accounts for around 2% of I-Tech's sales and ~10% of its TAM.Remain positive on long-term prospectsWe believe it is likely that the draft will be approved, however, we remain positive on the company's long-term outlook given its small exposure to the EU market. That said, there is always a risk that a ban could have a negative impact on I-Tech's attempts to enter other markets, such as the US (although this is a small market), or on re-application processes in regions where it has already achieved approval (most importantly Japan, South Korea, China). There is also the risk that paint companies may be deterred from using Selektope in other markets as well.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.